MCID: OLF005
MIFTS: 48

Olfactory Neuroblastoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Smell/Taste diseases

Aliases & Classifications for Olfactory Neuroblastoma

MalaCards integrated aliases for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma 12 52 58 15 17 71
Esthesioneuroblastoma 12 74 52 58 54
Paranasal Sinus Olfactory Neuroblastoma 12
Esthesioneuroblastoma, Olfactory 43
Olfactory Esthesioneuroblastoma 12
Esthesioneuroepithelioma 12
Asthesioneuroblastoma 12

Characteristics:

Orphanet epidemiological data:

58
esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:369
MeSH 43 D018304
NCIt 49 C3789
SNOMED-CT 67 422886007
ICD10 via Orphanet 33 C30.0
UMLS via Orphanet 72 C0206717
Orphanet 58 ORPHA1957
UMLS 71 C0206717

Summaries for Olfactory Neuroblastoma

NIH Rare Diseases : 52 Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses . It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses . It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood. Symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor , facial pain, runny nose, and nosebleeds. Treatment usually includes surgery to remove the tumor, radiation therapy , and sometimes chemotherapy .

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to nasal cavity olfactory neuroblastoma and sinonasal undifferentiated carcinoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Neuroscience. The drugs Cevimeline and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and brain, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Esthesioneuroblastoma, is a rare cancer of the nasal cavity. Arising from the upper nasal tract,... more...

Related Diseases for Olfactory Neuroblastoma

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 463)
# Related Disease Score Top Affiliating Genes
1 nasal cavity olfactory neuroblastoma 34.5 SYP NKX2-1 ENO2
2 sinonasal undifferentiated carcinoma 31.3 SYP ENO2
3 adrenal neuroblastoma 30.6 SYP NTRK1 ENO2
4 intracranial cysts 30.6 S100B ENO2
5 paraganglioma 30.5 SYP S100B ENO2 CHGA
6 lung oat cell carcinoma 30.4 SYP ENO2 CHGA
7 central neurocytoma 30.4 SYP ENO2 CHGA
8 ganglioneuroblastoma 30.1 SYP S100B NTRK1 ENO2
9 pituitary adenoma, prolactin-secreting 30.1 SSTR2 NGFR CHGA
10 hemangioma 30.1 SYP NKX2-1 ENO2 CHGA
11 neuroendocrine carcinoma 30.1 SYP S100B PTPRC NKX2-1 ENO2 CHGA
12 malignant teratoma 30.1 SYP ENO2 CD99
13 neuroendocrine tumor 30.0 SYP SSTR2 NKX2-1 ENO2 CHGA
14 askin's tumor 29.8 SYP NTRK1 EWSR1 ENO2 CD99
15 adenoma 29.8 SYP SSTR2 CHGA CCND1
16 carcinosarcoma 29.7 VIM MB CALB2
17 gangliocytoma 29.7 SYP ENO2
18 small cell carcinoma 29.6 SYP PTPRC NKX2-1 ENO2 CHGA
19 plasmacytoma 29.5 SYP PTPRC CCND1
20 neuroblastoma 29.5 SYP SSTR2 SHH NTRK1 NGFR EWSR1
21 small cell cancer of the lung 29.3 SYP SSTR2 PTPRC NKX2-1 ENO2 CHGA
22 ganglioneuroma 29.3 SYP S100B NTRK1 ENO2 CHGA CD99
23 meningioma, familial 29.2 SYP SSTR2 SHH ENO2 CCND1
24 merkel cell carcinoma 29.0 SYP PTPRC NKX2-1 ENO2 CHGA CD99
25 sarcoma 28.9 VIM S100B PTPRC EWSR1 ENO2 CCND1
26 leiomyosarcoma 28.5 VIM S100B PTPRC MB ENO2 CCND1
27 pheochromocytoma 28.5 SYP NTRK1 NGFR ENO2 CHGA CCND1
28 teratoma 28.2 VIM SYP SHH NKX2-1 ENO2 CHGA
29 ewing sarcoma 28.2 VIM SYP S100B PTPRC EWSR1 ENO2
30 rhabdomyosarcoma 26.9 VIM SYP SHH S100B PTPRC MB
31 malignant melanocytic neoplasm of the peripheral nerve sheath 10.6 SYP ENO2
32 vaginal glandular tumor 10.5 ENO2 CHGA
33 ureter transitional cell carcinoma 10.5 ENO2 CHGA
34 glomangioma 10.5 VIM SYP
35 anal neuroendocrine tumor 10.5 SYP ENO2
36 cerebral neuroblastoma 10.5 SYP ENO2
37 multiple mucosal neuroma 10.5 NTRK1 ENO2
38 pineal region teratoma 10.5 SYP ENO2
39 rare tumor 10.5
40 bile duct mucinous adenocarcinoma 10.5 SYP ENO2
41 goblet cell carcinoid 10.5 ENO2 CHGA
42 acinar cell cystadenocarcinoma 10.5 SYP CHGA
43 vulvar eccrine porocarcinoma 10.5 SYP CHGA
44 nodular prostate 10.5 SYP ENO2
45 cervical large cell neuroendocrine carcinoma 10.5 SYP CHGA
46 gastric gastrinoma 10.5 ENO2 CHGA
47 gastrointestinal neuroendocrine benign tumor 10.5 SYP CHGA
48 nodular ganglioneuroblastoma 10.5 ENO2 CHGA
49 cerebellar liponeurocytoma 10.5 SYP ENO2
50 mixed ductal-endocrine carcinoma 10.5 SYP CHGA

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:



Diseases related to Olfactory Neuroblastoma

Symptoms & Phenotypes for Olfactory Neuroblastoma

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 10.19 SSTR2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-123 10.19 CHGA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-126 10.19 CCND1 EWSR1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 10.19 EWSR1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-140 10.19 EWSR1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-146 10.19 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.19 CCND1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-163 10.19 CCND1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 10.19 SSTR2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 10.19 CHGA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-176 10.19 CHGA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.19 CCND1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.19 SSTR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.19 CCND1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-199 10.19 CCND1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-215 10.19 CHGA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.19 CCND1 EWSR1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 10.19 CCND1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-52 10.19 EWSR1 NTRK1 SSTR2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.19 CCND1 EWSR1 SSTR2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-56 10.19 SSTR2
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.19 CHGA
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-70 10.19 CHGA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.19 EWSR1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 10.19 EWSR1
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.19 EWSR1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.19 CCND1 SSTR2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.8 CD99
29 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.8 ISL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.8 EWSR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.8 CD99 ISL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.8 CD99
33 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.8 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.8 ISL1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.8 CCND1 EWSR1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.8 EWSR1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.8 CD99
38 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.8 EWSR1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.8 CD99
40 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.8 EWSR1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.8 CCND1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.8 CCND1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.8 CCND1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.8 CD99
45 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.8 CCND1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.8 CD99
47 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.8 EWSR1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.8 ISL1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.8 ISL1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.8 ISL1

MGI Mouse Phenotypes related to Olfactory Neuroblastoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 CALB2 CCND1 ENO2 ISL1 NGFR NKX2-1
2 cardiovascular system MP:0005385 10.07 CCND1 CHGA ISL1 MB NGFR NKX2-1
3 nervous system MP:0003631 9.97 CALB2 CCND1 CHGA ENO2 ISL1 NGFR
4 digestive/alimentary MP:0005381 9.87 CCND1 ISL1 NGFR NKX2-1 PTPRC SHH
5 muscle MP:0005369 9.8 CHGA ISL1 MB NGFR NTRK1 SHH
6 normal MP:0002873 9.65 CALB2 CCND1 ISL1 NGFR NKX2-1 NTRK1
7 respiratory system MP:0005388 9.23 CCND1 ENO2 MB NGFR NKX2-1 PTPRC

Drugs & Therapeutics for Olfactory Neuroblastoma

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
2
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Promethazine Approved, Investigational Phase 3 60-87-7 4927
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Neurotransmitter Agents Phase 3
13 Liver Extracts Phase 3
14 Cola Phase 3
15 Muscarinic Agonists Phase 3
16 Cholinergic Agents Phase 3
17 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
18 Hormone Antagonists Phase 2, Phase 3
19 Antifungal Agents Phase 2, Phase 3
20 Central Nervous System Stimulants Phase 3
21 Contraceptives, Oral Phase 3
22 Antineoplastic Agents, Hormonal Phase 3
23 Contraceptive Agents Phase 3
24
Megestrol Phase 3 3562-63-8 19090 3080587
25 Antidepressive Agents Phase 3
26 Hypnotics and Sedatives Phase 3
27 Histamine Antagonists Phase 3
28 Psychotropic Drugs Phase 3
29
Histamine Phosphate Phase 3 51-74-1 65513
30 Antidepressive Agents, Tricyclic Phase 3
31 Anesthetics Phase 3
32 Narcotics Phase 3
33 Analgesics Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
38
Indinavir Approved Phase 2 150378-17-9 5362440
39
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
40
Lenograstim Approved, Investigational Phase 2 135968-09-1
41
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
42
Carmustine Approved, Investigational Phase 2 154-93-8 2578
43
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
44
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
45
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
48
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
49
Ifosfamide Approved Phase 2 3778-73-2 3690
50
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
2 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
3 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
4 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
5 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
6 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
8 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
9 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
10 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
11 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
12 CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
13 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
14 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
15 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
16 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
17 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
18 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
19 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
20 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
21 A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors Recruiting NCT03274414 Phase 2 Cisplatin;cisplatin and etoposide
22 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
23 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
24 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
25 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
26 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
27 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
28 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
29 Phase I Trial of NGR-TNF Administered Every 3 Weeks as a 1 Hour Intravenous Infusion in Patients With Solid Tumor Completed NCT00098943 Phase 1
30 Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
31 A Phase I Study of NX 211 in Combination With Cisplatin Given as an IV Infusion Days 1, 2, and 3 Every 3 Weeks in Patients With Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
32 A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol Completed NCT00004065 Phase 1 tanespimycin
33 VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER Completed NCT00019110 Phase 1
34 A Phase I Study of Oral Fluoropyrimidine Capecitabine (Xeloda Roche) Combined With Intravenous Cisplatin in Patients With Advanced Cancer of the Digestive System Completed NCT00010023 Phase 1 capecitabine;cisplatin
35 PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES AND VARYING DEGREES OF LIVER DYSFUNCTION Completed NCT00002901 Phase 1 docetaxel
36 Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies Completed NCT00045006 Phase 1 vorinostat
37 A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1 docetaxel;gemcitabine hydrochloride
38 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
39 A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Paclitaxel in Recurrent or Metastatic Carcinoma of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
40 Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles Completed NCT00049296 Phase 1 docetaxel;thalidomide
41 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
42 Phase I Trial of PC 4-PDT (NSC 676418) for Cutaneous Malignancies Terminated NCT00023790 Phase 1 silicon phthalocyanine 4
43 Phase I Study of the Pharmacokinetics and Pharmacodynamics of ZD6474 in Combination With Docetaxel in Advanced Solid Tumors Withdrawn NCT00937417 Phase 1 docetaxel;vandetanib
44 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
45 A Prospective Randomised Controlled Clinical Trial Investigating the Benefits of Patient-customised Headrests Versus Standard (Non-patient Specific) Headrests in the Immobilisation of Patients Receiving Radiotherapy for Head and Neck Cancer Completed NCT00973947
46 Establishment of a Head and Neck Cancer Tissue/Specimen Bank Completed NCT00898300
47 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
48 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 systemic chemotherapy
49 A Pilot Study of Functional Mapping and Brain Perfusion Imaging in Patients Receiving Base of Skull and Brain Radiotherapy: Developing Neurocognitive Functional Organs At Risk for Individualized Conformal Radiotherapy Completed NCT00984074
50 A Pilot Study of TGF-beta as a Potential Target for Prevention of Radiation-Induced Injury Completed NCT00897793

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Genetic Tests for Olfactory Neuroblastoma

Anatomical Context for Olfactory Neuroblastoma

MalaCards organs/tissues related to Olfactory Neuroblastoma:

40
Bone, Eye, Brain, Lung, Liver, Breast, Endothelial

Publications for Olfactory Neuroblastoma

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 1243)
# Title Authors PMID Year
1
Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma. 61 54
19386345 2009
2
[Advances in the diagnosis of ENT tumors in childhood]. 54 61
12724079 2003
3
[Co-expression of TrkA and p75 neurotrophin receptor in extracranial olfactory neuroblastoma cells]. 54 61
12934398 2003
4
Co-expression of trkA and p75 neurotrophin receptor in extracranial olfactory neuroblastoma cells. 61 54
12175342 2002
5
Primary mucosal melanomas of the nasal cavity and paranasal sinuses. A clinicopathological analysis of 14 cases. 54 61
9548430 1998
6
Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. 54 61
8630875 1995
7
Olfactory neuroblastoma. Additional immunohistochemical characterization. 54 61
1700595 1990
8
Insulinoma-associated protein 1 immunostaining for various types of neuroendocrine tumors on FNA smears. 61
32573984 2020
9
Surgical outcomes in patients with endoscopic versus transcranial approach for skull base malignancies: a 10-year institutional experience. 61
32538686 2020
10
Sinonasal carcinomas - A single-centre experience at Prince of Wales Hospital, Sydney, Australia, from 1994 to 2016. 61
32307914 2020
11
68Ga-DOTATATE and 18F-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival Region. 61
32558717 2020
12
Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma. 61
32558242 2020
13
Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience. 61
32500004 2020
14
Correction to: advanced olfactory neuroblastoma in a teenager: a clinical case and short review of literature. 61
32144489 2020
15
Primary Olfactory Neuroblastoma Masquerading as a Pituitary Adenoma : Case Report and Review of the Literature. 61
32385516 2020
16
Patient-reported outcomes, physician-reported toxicities, and treatment outcomes in a modern cohort of patients with sinonasal cancer treated using proton beam therapy. 61
32417351 2020
17
Tumour-to-tumour metastasis: breast carcinoma to an olfactory neuroblastoma. 61
32374183 2020
18
Management of olfactory neuroblastoma, neuroendocrine carcinoma, and sinonasal undifferentiated carcinoma involving the skullbase. 61
32424573 2020
19
Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma. 61
32126517 2020
20
Primary sellar neuroblastoma mimicking invasive pituitary adenoma: a systematic review. 61
32347676 2020
21
Comparing Kadish and Modified Dulguerov Staging Systems for Olfactory Neuroblastoma: An Individual Participant Data Meta-analysis. 61
32286935 2020
22
Olfactory neuroblastoma pulmonary metastasis presenting as a solitary pulmonary mass in an adult: A case report with pathologic correlation. 61
31993094 2020
23
Pattern of loco-regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution. 61
31930719 2020
24
Chemotherapy in Esthesioneuroblastoma/Olfactory Neuroblastoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) 1973-2015 Database. 61
31842117 2020
25
Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. 61
31785431 2020
26
Advanced olfactory neuroblastoma in a teenager: a clinical case and short review of literature. 61
31989207 2020
27
Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma with Ectopic Cushing's Syndrome. 61
32102127 2020
28
Extensive tumor calcification in response to pre-operative reductive chemotherapy in pediatric esthesioneuroblastoma: a case report. 61
32100079 2020
29
Remote Leptomeningeal Dissemination in Olfactory Neuroblastoma Mimicking Multiple Parasagittal Meningiomas: Diagnostic and Therapeutic Challenge. 61
31734430 2020
30
Rare neural crest tumor in teleost species: olfactory neuroblastoma in a spotted pike-characin Boulengerella maculata. 61
32052792 2020
31
[Analysis of the effect of endoscopic surgery combined with conventional surgery in Neuroblastoma]. 61
32086916 2020
32
Neck management in patients with olfactory neuroblastoma. 61
31835073 2020
33
Mixed olfactory neuroblastoma and neuroendocrine carcinoma: An unusual case report and literature review. 61
32494376 2020
34
Fibroblast Growth Factor 23-Producing Phosphaturic Mesenchymal Tumor with Extraordinary Morphology Causing Oncogenic Osteomalacia. 61
31963334 2020
35
Treatment and outcome in 12 cases of olfactory neuroblastoma at Mexico´s National Cancer Institute: A retrospective clinical analysis and literature review. 61
32567594 2020
36
Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. 61
32005769 2020
37
[Treatment of primary craniofacial (sinonasal) malignant tumors affecting the anterior and middle skull base]. 61
32207749 2020
38
Evaluating the prognostic potential of the Ki67 proliferation index and tumour-infiltrating lymphocytes in olfactory neuroblastoma. 61
31306501 2019
39
Clinical outcomes, ultrastructure and immunohistochemical features of canine high-grade olfactory neuroblastoma. 61
31177641 2019
40
[Spectrum analysis of pathological classification in 463 cases with nasal and paranasal sinuses malignant tumors]. 61
31914269 2019
41
Recurrence patterns of sinonasal cancers after a 5-year disease-free period. 61
30794325 2019
42
Endonasal endoscopic skullbase surgery in children. 61
31079184 2019
43
DNA methylation-based classification of sinonasal undifferentiated carcinoma. 61
31186531 2019
44
An atypical presentation of a Respiratory Epithelial Adenomatoid Hamartoma, a case report. 61
31528338 2019
45
Olfactory neuroblastoma (esthesioneuroblastoma) presenting as ectopic ACTH syndrome: always follow your nose. 61
31627184 2019
46
Secondary extradural spinal manifestation of esthesioneuroblastoma. 61
29086605 2019
47
Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. 61
31251848 2019
48
Septal Flip Flap for Anterior Skull Base Reconstruction After Endoscopic Transnasal Craniectomy: Long-Term Outcomes. 61
31042605 2019
49
Hormonal Fertility Therapy as Potential Risk Factor for Cerebrospinal Fluid Leak After Endoscopic Endonasal Surgery: Case Study and Literature Review. 61
31132487 2019
50
Ectopic primary olfactory neuroblastoma of the nasopharynx: A case report and review of the literature. 61
31198483 2019

Variations for Olfactory Neuroblastoma

Copy number variations for Olfactory Neuroblastoma from CNVD:

7 (show all 31)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 31526 1 28000000 30200000 Gain Olfactory neuroblastoma
2 34250 1 5400000 7200000 Gain Olfactory neuroblastoma
3 41470 10 18700000 22600000 Gain Olfactory neuroblastoma
4 63735 12 120700000 125900000 Gain Olfactory neuroblastoma
5 74688 13 110300000 115169878 Gain CUL4A Olfactory neuroblastoma
6 74689 13 110300000 115169878 Gain TFDP1 Olfactory neuroblastoma
7 75167 13 17900000 115169878 Gain Olfactory neuroblastoma
8 77744 13 47300000 55300000 Gain Olfactory neuroblastoma
9 79881 13 79000000 87700000 Gain Olfactory neuroblastoma
10 91527 15 31200000 33600000 Gain Olfactory neuroblastoma
11 101890 16 47000000 52600000 Gain Olfactory neuroblastoma
12 150427 20 1 27500000 Gain Olfactory neuroblastoma
13 151980 20 27500000 63025520 Gain Olfactory neuroblastoma
14 152120 20 29400000 37600000 Gain Olfactory neuroblastoma
15 154980 20 5100000 12100000 Gain Olfactory neuroblastoma
16 155529 20 56500000 63025520 Gain BRK Olfactory neuroblastoma
17 159453 21 42600000 48129895 Gain Olfactory neuroblastoma
18 163221 22 25900000 29600000 Gain Olfactory neuroblastoma
19 179990 4 1 6000000 Gain Olfactory neuroblastoma
20 181394 4 120800000 191154276 Gain Olfactory neuroblastoma
21 184608 4 17800000 48200000 Gain Olfactory neuroblastoma
22 187607 4 52700000 59500000 Gain Olfactory neuroblastoma
23 190046 4 82400000 93700000 Gain Olfactory neuroblastoma
24 196156 5 159900000 168500000 Gain Olfactory neuroblastoma
25 196538 5 168500000 180915260 Gain Olfactory neuroblastoma
26 213457 6 46200000 51800000 Gain Olfactory neuroblastoma
27 227898 7 72200000 77500000 Gain FZD9 Olfactory neuroblastoma
28 227899 7 72200000 77500000 Gain LIMK1 Olfactory neuroblastoma
29 228591 7 77500000 86400000 Gain Olfactory neuroblastoma
30 251884 9 33200000 36300000 Gain Olfactory neuroblastoma
31 257109 X 1 155270560 Gain Olfactory neuroblastoma

Expression for Olfactory Neuroblastoma

Search GEO for disease gene expression data for Olfactory Neuroblastoma.

Pathways for Olfactory Neuroblastoma

Pathways related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.23 NTRK1 NKX2-1 NGFR CCND1
2 11.97 SYP S100B NTRK1 NKX2-1 NGFR ENO2
3 11.66 VIM NGFR CCND1
4 11.58 VIM SHH NGFR ISL1
5
Show member pathways
11.22 NTRK1 NGFR CCND1
6 10.92 VIM SYP SHH S100B ISL1
7 10.28 SHH NKX2-1

GO Terms for Olfactory Neuroblastoma

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.56 SHH NTRK1 NKX2-1 NGFR
2 anatomical structure formation involved in morphogenesis GO:0048646 9.48 SHH NKX2-1
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.46 SHH NKX2-1
4 negative thymic T cell selection GO:0045060 9.43 SHH PTPRC
5 positive thymic T cell selection GO:0045059 9.4 SHH PTPRC
6 Leydig cell differentiation GO:0033327 9.37 NKX2-1 CCND1
7 forebrain development GO:0030900 9.33 SSTR2 SHH NKX2-1
8 Bergmann glial cell differentiation GO:0060020 9.32 VIM SHH
9 stem cell development GO:0048864 8.96 SHH PTPRC
10 neuron fate commitment GO:0048663 8.8 SHH NKX2-1 ISL1

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nerve growth factor binding GO:0048406 8.96 NTRK1 NGFR
2 neurotrophin binding GO:0043121 8.62 NTRK1 NGFR

Sources for Olfactory Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....